USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: IMMUCELL CORPORATION
City: PORTLAND
State: ME
Zip+4: 04103
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: (207) 878-2770

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $877,271.00 9
SBIR Phase II $1,646,568.00 3

Award List:

IMMUNOTHERAPY FOR CRYPTOSPORIDIUM INFECTIONS

Award Year / Program / Phase: 1990 / SBIR / Phase I
Agency: HHS
Principal Investigator: Joseph H Crabb
Award Amount: $50,000.00
Abstract:
The number of cases of human diarrhea attributed to cryptosporidium parvum has increased dramatically in the last decade. in immunocompromised individuals, most notablyaids patients, cryptosporidiosis can present as a fulminant and persistent diarrhea. there is currently no known chemotherapeutic… More

IDENTIFYING CRYPTOSPORIDIUM PROTECTIVE ANTIGEN GENES

Award Year / Program / Phase: 1992 / SBIR / Phase I
Agency: HHS
Principal Investigator: Samuel A Lewis
Award Amount: $49,941.00

STRAIN SPECIFICITY OF ANTI-CRYPTOSPORIDIUM IGG

Award Year / Program / Phase: 1992 / SBIR / Phase I
Agency: HHS
Principal Investigator: Joseph H Crabb
Award Amount: $50,000.00

IDENTIFYING CRYPTOSPORIDIUM PROTECTIVE ANTIGEN GENES

Award Year / Program / Phase: 1994 / SBIR / Phase II
Agency: HHS
Principal Investigator: Samuel A Lewis
Award Amount: $490,365.00
Abstract:
Cryptosporidium parvum is a significant human pathogen whose incidence has increased dramatically in the last decade and that currently infects approximatly 10% of aids patients inthe u.s. mortality due to this parasite exceeds 60% of infected immunocompromised patients. no therapeutic drugs are… More

STRAIN SPECIFICITY OF ANTI-CRYPTOSPORIDIUM IGG

Award Year / Program / Phase: 1994 / SBIR / Phase II
Agency: HHS
Principal Investigator: Joseph H Crabb
Award Amount: $446,482.00
Abstract:
Cryptosporidium parvum is a significant human pathogen for which no chemotherapy has been shown to be efficacious. the number of cases of human cryptosporidiosis has increased dramatically in the last decade, particularly in the population of immuno-compromised individuals. in the aids population,… More

Travelers Diarrhea and E Coli--Prevalence of Pilus AGS

Award Year / Program / Phase: 1995 / SBIR / Phase I
Agency: HHS
Principal Investigator: Daniel Freedman
Award Amount: $100,000.00

IMPROVED METHOD OF MONITORING WATER FOR CRYPTOSPORIDIUM

Award Year / Program / Phase: 1996 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $100,000.00

Travelers Diarrhea and E Coli--Prevalence of Pilus AGS

Award Year / Program / Phase: 1997 / SBIR / Phase II
Agency: HHS
Principal Investigator: Daniel Freedman
Award Amount: $709,721.00
Abstract:
Enterotoxigenic E. coli (ETEC) is among the most important agents involved in pediatric diarrhea anmost frequently encountered cause of illness in visitors to these regions. It is estimated that 16 mindustrialized nations travel to ETEC-endemic regions annually, and that 30-70% of these travelers… More

A Novel Dry Cow Therapy

Award Year / Program / Phase: 2001 / SBIR / Phase I
Agency: USDA
Principal Investigator: Richard T. Coughlin
Award Amount: $70,000.00
Abstract:
Bovine mastitis is a major economic loss for the dairy industry and indirectly a human hazard because treatment selects for antibiotic resistant bacteria. We propose to develop an novel anti-microbial therapy for dry cow mastitis based on Nisin that would break farmer's dependence on antibiotics… More

Immunomagnetic Separation Assay for Mycobacterium Paratuberculosis

Award Year / Program / Phase: 2001 / SBIR / Phase I
Agency: USDA
Principal Investigator: Joseph H. Crabb
Award Amount: $70,000.00
Abstract:
Johne's disease, caused by Mycobacterium paratuberculosis (M. para), is a chronic inflamatory bowel disease of ruminants. recent literature has fueled an as-yet unresolved debate about whether this organism is also the eitiological agent of at least some proportion of Crohn's Disease in humans.… More

NOVEL ANTIMICROBIAL TREATMENT FOR MASTITIS

Award Year / Program / Phase: 2001 / SBIR / Phase I
Agency: HHS
Principal Investigator: Richard T. Coughlin
Award Amount: $196,247.00
Abstract:
The development of stategies and products to prevent the spread of antibiotic resistance is a national priority. A significant contributing factor in the rise of antibiotic resistance is the agricultural application of antibiotics which are used to treat human disease. We propose to… More

JENSENIIN P AND NISIN TO TREAT TOPICAL INFECTIONS

Award Year / Program / Phase: 2002 / SBIR / Phase I
Agency: HHS
Principal Investigator: Richard T. Coughlin
Award Amount: $191,083.00
Abstract:
Developing strategies and products to prevent the spread of antibiotic resistance is a national priority. A significant contributing factor in the rise of antibiotic resistance is the use of antibiotics to treat diseases which are not life threatening. We propose to develop two novel anti-microbial… More